The biopharma sector is facing a significant wave of layoffs in 2024, affecting thousands of employees across various companies. This trend is shaped by numerous internal and external factors, including corporate restructuring, market adaptations, strategic divestments, and cost-saving measures.
The biopharmaceutical manufacturing sector stands at the brink of a revolution, driven by the relentless pursuit of speed, safety, and scalability. The emergence of new therapeutic modalities, coupled with the increasing demand for rapid and cost-effective production solutions, has necessitated a
The approval of Bluebird bio's gene therapy, Skysona, in September 2022 by the FDA marked a significant milestone for treating cerebral adrenoleukodystrophy (CALD), a rare and fatal childhood brain disorder. Skysona's innovation generated hope for families dealing with CALD, yet recent developments
In an ambitious endeavor to revolutionize cancer treatment, Boehringer Ingelheim and Circle Pharma have entered into a research partnership and license agreement aimed at developing a first-in-class cyclin inhibitor. This groundbreaking collaboration is set to provide novel treatment options for
The landscape of cancer treatment is ever-evolving, with new therapies continually pushing the boundaries of what is possible. Kiromic BioPharma's latest advancement, Deltacel, an allogeneic gamma delta T-cell (GDT) therapy, is showing significant promise in the treatment of advanced non-small cell
The landscape of respiratory syncytial virus (RSV) vaccination has seen significant developments with GSK's Arexvy vaccine leading the charge. Dive deep into the three-year efficacy data released by GSK, and understand what it means for the future of RSV vaccination, market dynamics, and public
The field of spinal muscular atrophy (SMA) treatment has been dynamically evolving, and the latest breakthrough stems from Scholar Rock's Phase 3 clinical trial of apitegromab. This experimental drug is designed to preserve muscle function, representing a potential new standard of care for SMA
BioHub Maryland recently announced a significant development in its mission to bolster the biopharma workforce within the state. Securing a $75,000 grant under the EARN Maryland program, an initiative supported by the Maryland Department of Labor, the organization will use these funds to train
The biopharmaceutical industry is a dynamic and complex sector that has seen exponential growth over recent years. Central to this growth is the practice of outsourcing various elements of the biopharma process, from raw material sourcing to finished drug development. This article delves into how
Legend Biotech is poised to enhance its cell therapy research and development capabilities with the establishment of a new R&D site in Philadelphia's Center City district. Scheduled to open by the third quarter of 2025, the 31,000-square-foot facility will employ around 55 full-time workers and be
